Research On Drug Safety Supervision Of China

Since the 1998 reform, Drug Administration of China has basically established the unified leadership of the Central Government, vertical management below the provincial level drug supervision and management system, optimized the administrative allocation of resources to some extent, and improved the efficiency of supervision. However, China's drug safety issues have not been effectively resolved. In recent years, with the rapid development of the pharmaceutical industry, drug safety accidents have also occurred, frequently, a completely shocking incidents of drug safety of the public continue to touch the fragile nerves, the people's attention away from the hold down prices and medical treatment and expensive to attract up to drug safety issues. In 2008, in the agency and adjustments, the food and drug administration, return to the department of health management, medical management system, which reflects our ten years vicissitude drug supervision and management system construction of difficulties. As the first responsible person, Counterfeit and substandard drugs manufacturers should be blamed. However, as regulatory authorities who approved counterfeit or substandard drugs to market is difficult to pass the buck. Drug safety incidents occur there is no lack of enterprise through the "Good Manufacturing Practices" (GMP) of the enterprise, drug regulators have been sacked senior staff, which all exposed in our drug regulatory loopholes. The concentration of drug safety incidents occurred not only make the public lose confidence in the drug market, and let the public to doubt our government administrative capacity. The fifth part, firstly analyzed the incentive missing in the multiple principal-agent relationship, then constructed two incentive compatible models for the main part of chain of drug safety regulations, which is The State Department and regulatory agencies, regulatory agencies and pharmaceutical companies; Partâ…¥, the conclusions drawn in this paper. In this part we analysis the main question of drug safety regulation in China.New long-term goal of health reform makes the safety factor in the first. In theory, build a scientific and effective monitoring mechanism, the key is to properly handle the issue of information efficiency and incentive compatibility. Constructing China's national conditions for drug safety supervision system, the key is to change the traditional restrictive regulatory approach, reconstruction encompassing interest, and establish a political incentive to avoid regulatory capture mechanism to encourage drug companies to improve drug quality system. With the establishment of incentive-compatible system, consumers, State Department, drug safety regulators, drug companies, the four stakeholders in the new institutional framework will pursue their own utility maximization, which will also promote the implementation of social welfare maximization. In summary, the article is based on the looking for the root cause of the drug safety accident, introducing incentive mechanisms to all the principal-agent relationships, making use of a new incentive mechanism between the interests of all of the main objectives in line.